Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20530637 | 1.00 | EPHX2 (0.42) | EPHX2KMT2ACHRM3MDM2CASP3 | |
| SCHEMBL30466803 | 0.90 | EPHX2 (0.47) | EPHX2KMT2ACHRM3CASP3EPHX1 | |
| SCHEMBL20530636 | 0.90 | EPHX2 (0.47) | EPHX2KMT2ACHRM3CASP3EPHX1 | |
| SCHEMBL30466805 | 0.89 | MTNR1A (0.42) | EPHX2KMT2AMDM2CASP3MDM4 | |
| SCHEMBL20530643 | 0.89 | MTNR1A (0.42) | EPHX2KMT2AMDM2CASP3MDM4 | |
| SCHEMBL20530658 | 0.89 | EPHX2 (0.42) | EPHX2KMT2ACHRM3CASP3MDM4 | |
| SCHEMBL30466815 | 0.89 | EPHX2 (0.42) | EPHX2KMT2ACHRM3CASP3MDM4 | |
| SCHEMBL20530646 | 0.86 | PTGDR2 (0.41) | EPHX2KMT2ACHRM3MDM2 | |
| SCHEMBL30466807 | 0.86 | PTGDR2 (0.41) | EPHX2KMT2ACHRM3MDM2 | |
| SCHEMBL20530629 | 0.86 | CHRM3 (0.45) | EPHX2KMT2ACHRM3MDM2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110494442-B | Peptide macrocycles and their use in the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2023-07-25 | — | — | CN | disclosed |